Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiation
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.